Senseonics (SENS) Small-Cap Growth Virtual Investor Conference summary

Market overview and growth drivers

• Continuous glucose monitoring (CGM) market projected to reach $15 billion next year, growing at 25% annually due to payer recognition and expanding reimbursement.

• Over half of Type 1 diabetes patients use CGM; Type 2 market penetration is lower but expanding, especially with new reimbursement for basal insulin users.

• Only 25% overall CGM penetration in the U.S., leaving significant room for growth and differentiation.

• Patients seek longer-lasting sensors and solutions that eliminate on-body components.

• CGM adoption is driven by clinical benefits, payer support, and patient demand for convenience.

Product innovation and pipeline

• Current product offers 180-day sensor life; 365-day (one-year) sensor is under FDA review and expected to launch soon.

• Next-generation Gemini product targets both Type 1 (with transmitter) and Type 2 (standalone, no transmitter) diabetes, with first human trials planned soon and commercial launch aimed for 2026.

• Freedom system will integrate one-year sensor, battery, and Bluetooth for real-time phone connectivity, targeting both Type 1 and Type 2 users.

• Product roadmap includes sunsetting current generation in favor of the 365-day sensor, followed by Gemini and Freedom launches.

• Focus on eliminating on-body components and improving user discretion and compliance.

Partnerships and commercialization

• Commercialization handled by Ascensia Diabetes Care, which manages sales, marketing, and distribution; revenue is shared, with most going to Senseonics.

• Nurse practitioner network enables flexible sensor insertion in clinics or at home.

• Partnership with Mercy, a major hospital system, aims to deploy CGM to 30,000 patients using remote patient monitoring and AI analytics integrated with Epic.

• Multi-channel marketing includes direct-to-consumer advertising, professional sales, and hospital system contracts.

• Remote patient monitoring solution targets at-risk Type 2 patients, aiming to reduce costly emergency interventions.